The Government has said that it will be publishing a National Cancer Plan, as recommended by the predecessor Health and Social Care Committee.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Subcutaneous daratumumab reduced the risk for disease progression or death vs active monitoring in intermediate- or high-risk smoldering multiple myeloma.
A pooled analysis of 9548 HNC cases and 15,783 controls from the International Head and Neck Cancer Epidemiology consortium was conducted to assess the association…
Colorectal Cancer provides a concise, readable overview of current and future management options in a fast-moving field, ideal for the busy clinician or healthcare professional.…
This Viewpoint discusses the importance of formulating more stable local treatment guidelines because international guidelines and even resource-stratified guidelines may not be as applicable in…
Register now and explore groundbreaking advancements in acute leukemia and myelodysplasia treatment at ALF 2025. Stay informed with the latest innovations shaping the future of…
Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.
Jorge Cortes, MD director of the Georgia Cancer Center at Augusta University and inaugural Editor-in-Chief of Blood Global Hematology, shares his vision for the journal…
In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in light-chain (AL) amyloidosis. Dr…
Welcome to the International Journal of Cancer Symposium on Principles of Chromatin Remodeling in Cancer and Translational Perspectives Tight regulation of the spatial and temporal…
